Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 12, 2024

Sensitivity and Prognostic Utility of Serum FLC vs FLC-MS Assessments in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma Treated With Chemotherapy

Blood Cancer Journal

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood Cancer Journal
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
Blood Cancer J 2024 Mar 18;14(1)50, HV Giles, MT Drayson, B Kishore, C Pawlyn, M Kaiser, G Cook, R de Tute, RG Owen, D Cairns, T Menzies, FE Davies, GJ Morgan, G Pratt, GH Jackson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading